A feasibility study conducted by the University of Queensland (UQ) confirmed the utility of Inoviq Ltd.’s exosome-based ovarian cancer screening test for isolating extracellular vesicle (EV) biomarkers. The Ovarian Cancer 97 study (OC97) screened data from 97 plasma samples and identified significant differences between the EV biomarker content of ovarian cancer and healthy control samples.
Bertis Co. Ltd.’s artificial intelligence (AI)-based diagnosis model is able to detect diseases, such as cancers, with more than 95% accuracy, according to preliminary testing results reported at the Human Proteome Organization 2022 meeting in Cancun, Mexico on Dec. 8.
Ovarian cancer is ordinarily associated with poor survival; patients diagnosed with high-grade serous ovarian carcinoma (HGSC) have an overall survival of about 40% at 5 years and 15% at 10 years. Despite having similar histologic features, HGSC patients often experience highly variable outcomes and the underlying determinants for long-term survival (LTS) are largely unknown. In a study published online in Nature Genetics, a multi-institutional group of researchers tried to determine the molecular differences that drive LTS in patients with HGSC.
Ovarian cancer is ordinarily associated with poor survival; patients diagnosed with high-grade serous ovarian carcinoma (HGSC) have an overall survival of about 40% at 5 years and 15% at 10 years. Despite having similar histologic features, HGSC patients often experience highly variable outcomes and the underlying determinants for long-term survival (LTS) are largely unknown. In a study published online in Nature Genetics, a multi-institutional group of researchers tried to determine the molecular differences that drive LTS in patients with HGSC.
Pancreatic cancer is the deadliest of cancers with just one in nine patients surviving five years after diagnosis. The low rate of survival largely results from the late stage at which the cancer is first detected, as 65% patients are not diagnosed until the disease has metastasized. Bluestar Genomics Inc. hopes it has developed an assay that can detect the cancer much sooner, allowing patients and their physicians to get ahead of the malignancy well before it spreads.
Previous research has shown that cytotoxic lymphocytes rely on gasdermin-mediated pyroptosis to kill tumor cells. Pyroptosis appears to be closely involved in anticancer immune response and has therefore emerged as a promising strategy for cancer treatment. In a recently published study, scientists at the University of Wisconsin-Madison aimed to leverage gasdermin-triggered pyroptosis for antitumor immunotherapy.
Molecure SA has received clearance from the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products to conduct the first clinical trial of OATD-02.
Xuanzhu Pharma Co. Ltd. has described tricyclic ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Sunshine Biopharma Inc. has entered into a collaboration agreement with a leading lipid nanoparticle (LNP) formulation company to advance the development of Sunshine's mRNA-based anticancer macromolecule, K1.1.
